Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Other Non-Current Liabilities (2016 - 2025)

Amicus Therapeutics filings provide 16 years of Other Non-Current Liabilities readings, the most recent being $4.2 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 41.12% to $4.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.2 million, a 41.12% decrease, with the full-year FY2025 number at $4.2 million, down 41.12% from a year prior.
  • Other Non-Current Liabilities hit $4.2 million in Q4 2025 for Amicus Therapeutics, down from $8.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $27.3 million in Q2 2021 to a low of $71000.0 in Q4 2023.
  • Median Other Non-Current Liabilities over the past 5 years was $9.0 million (2023), compared with a mean of $11.5 million.
  • The widest YoY moves for Other Non-Current Liabilities: up 17972.29% in 2023, down 99.67% in 2023.
  • Amicus Therapeutics' Other Non-Current Liabilities stood at $20.3 million in 2021, then grew by 5.3% to $21.4 million in 2022, then plummeted by 99.67% to $71000.0 in 2023, then soared by 9895.77% to $7.1 million in 2024, then tumbled by 41.12% to $4.2 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $4.2 million (Q4 2025), $8.5 million (Q1 2025), and $7.1 million (Q4 2024) per Business Quant data.